Regulatory

Where peptide compounding rules stand after the 2026 FDA votes

The FDA spent 2026 deciding which bulk peptides pharmacies may compound. Here is what changed, what the July advisory votes did, and why the rules still leave most research peptides unapproved.

SafePeptideUseJuly 28, 20261 min read

Key takeaways

In April 2026 the FDA removed BPC-157 and TB-500 from its Category 2 bulk drug list after the nominations were withdrawn. Neither moved to the approved Category 1, and neither is an approved drug.
On July 23 and 24 2026 the FDA's Pharmacy Compounding Advisory Committee met to decide which bulk peptides pharmacies may compound, and voted on several by narrow margins.
The overall direction has been toward tightening compounding access, not opening it up.
Whatever a list says, an unapproved research peptide is still unregulated, so a third party Certificate of Analysis still matters.

What changed in 2026

Compounding is the process where a licensed pharmacy makes a drug from a bulk ingredient. For peptides, whether a pharmacy may do this depends on lists the FDA maintains, and those lists moved a lot this year.

In April 2026 the FDA removed BPC-157 and TB-500 from its Category 2 list of bulk drug substances, after the people who had nominated them withdrew the nominations. Removal from Category 2 did not make them approved. Neither compound went onto the approved Category 1 list, and neither is an approved drug. They remain unapproved research compounds.

Sources:s1

What the July advisory votes did

On July 23 and 24 2026 the FDA's Pharmacy Compounding Advisory Committee met to weigh a batch of bulk peptides and recommend which ones pharmacies should be allowed to compound. The votes were close, and the committee backed some peptides while rejecting others.

An advisory committee recommends, it does not write final rules. The FDA takes these votes into account and decides later. What the meeting signaled is a cautious mood, with the burden on each peptide to prove it belongs on a compounding list rather than an assumption that it does.

Sources:s2, s3

What it means for you

The regulatory picture is still unsettled, and it is tightening rather than loosening. A compound coming off one list or getting rejected from another does not change the core fact that most research peptides are unapproved and unregulated.

That is exactly why product quality is on you. Before trusting any vial, check for a recent third party Certificate of Analysis with a batch number that matches what you have. The law may be in motion, but that habit protects you regardless of where the lists land.

Sources

[s1]Regulatory Affairs Professionals Society (RAPS) (2026). FDA considers adding a dozen peptides to its bulk drug compounding list. regulatory link
[s2]U.S. FDA (2026). July 23 to 24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. regulatory link
[s3]Partnership for Safe Medicines (2026). FDA peptide panel narrowly votes to add unapproved drugs to compounding list (27 July 2026). other link